Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 12/20 | 0.43 |
| ▸ | CCKBR | P32239 | 4/20 | 0.42 |
| ▸ | CCKAR | P32238 | 3/20 | 0.42 |
| ▸ | BDKRB1 | P46663 | 3/20 | 0.42 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14084920 | 1.00 | RIPK1 (0.43) | RIPK1CCKBRCCKARBDKRB1CCNA2 | |
| SCHEMBL6045877 | 0.90 | SCN9A (0.44) | RIPK1CCKBRCCKAR | |
| SCHEMBL4701105 | 0.88 | CCKBR (0.40) | RIPK1CCKBRCCKARBDKRB1CCNA2 | |
| SCHEMBL14084953 | 0.88 | BDKRB1 (0.42) | RIPK1BDKRB1CCNA2CDK2CCNA1 | |
| SCHEMBL6045927 | 0.87 | BDKRB1 (0.46) | BDKRB1CCNA2CDK2CCNA1 | |
| SCHEMBL14084972 | 0.87 | BDKRB1 (0.41) | RIPK1BDKRB1CCNA2CDK2CCNA1 | |
| SCHEMBL14084952 | 0.86 | BDKRB1 (0.42) | RIPK1CCKBRBDKRB1CCNA2CDK2 | |
| SCHEMBL6045945 | 0.86 | RIPK1 (0.41) | RIPK1CCKBRCCKARBDKRB1 | |
| SCHEMBL14084905 | 0.86 | RIPK1 (0.61) | RIPK1 | |
| SCHEMBL6045929 | 0.85 | BDKRB1 (0.47) | BDKRB1CCNA2CDK2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060281733-A1 | 4-Bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carvoxylic acid amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases | ELAN PHARMACEUTICALS, INC. | 2006-12-14 | — | — | US | claimed |
| US-20060281733-A1 | 4-Bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carvoxylic acid amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases | ELAN PHARMACEUTICALS, INC. | 2006-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281733-A1 | 4-Bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carvoxylic acid amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases | BDKRB1, BDKRB2, CNR1 | RIPK1 2259/4885CCKBR 36/4885CCKAR 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.